In 263 participants with relapsing MS on background disease-modifying therapy, opicinumab added for 72 weeks did not significantly improve the Overall Disability Response Score vs placebo (mean difference 0.15; p=0.148). Adverse events: 86% vs 85%.
RCTn = 263
Calabresi et al. Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial